Company Profile
BeyondSpring, Inc. Stock Price, News & Catalysts
- Ticker:
- BYSI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.71 USD (-15.21%)
Close
Last updated: August 17, 2026
69.9M USD
Market cap
Why the stock is moving
Following the latest company update, “BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update”, BYSI closed down 15.2% at $0.7115 on Aug 17, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Clinical-Stage Oncology Company
BeyondSpring is a clinical-stage biopharmaceutical company developing therapies intended to improve outcomes for patients with cancer. Its lead program, plinabulin, is being evaluated across treatment settings where immune activation and combination therapy may enhance antitumor activity.
Plinabulin
Plinabulin is a small-molecule GEF-H1 activator designed to promote dendritic-cell maturation and stimulate antitumor immune responses. The candidate has been administered to more than 700 patients and is being developed for use with chemotherapy, immune checkpoint inhibitors, antibody-drug conjugates, and other cancer therapies.
Post-Immunotherapy NSCLC Strategy
BeyondSpring is developing plinabulin for patients with advanced non-small cell lung cancer whose disease has progressed after PD-1 or PD-L1 therapy. Clinical work has evaluated plinabulin with docetaxel and with a triplet regimen combining plinabulin, docetaxel, and pembrolizumab.
DUBLIN-4 Confirmatory Program
The planned DUBLIN-4 study is a randomized, double-blind Phase 3 trial expected to enroll approximately 442 patients with non-squamous, EGFR wild-type NSCLC following progression on immunotherapy. The study is designed to confirm the survival and tolerability findings observed in the earlier DUBLIN-3 program.
Combination Optionality
BeyondSpring is also studying the potential for plinabulin to complement antibody-drug conjugates, radiation, and other immune-based approaches. Preclinical research supports a strategy of using plinabulin to broaden immune engagement and potentially improve the durability of combination regimens.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of BeyondSpring, Inc. (BYSI)?
BeyondSpring, Inc. (BYSI) most recently closed at 0.71 USD, a -15.21% move versus the previous session.
What is the market cap of BeyondSpring, Inc. (BYSI)?
BeyondSpring, Inc. currently has a market capitalization of 69.9M USD on BioPharmSignal.
What does BeyondSpring, Inc. do?
Clinical-Stage Oncology Company BeyondSpring is a clinical-stage biopharmaceutical company developing therapies intended to improve outcomes for patients with cancer. Its lead program, plinabulin, is being evaluated across treatment settings where immune activation and combination therapy may enhance antitumor activity. Plinabulin Plinabulin is a...
On which exchange is BYSI stock listed?
BeyondSpring, Inc. (BYSI) is associated with NASDAQ, United States, Biopharma.
What is GEF-H1?
Plinabulin Plinabulin is a small-molecule GEF-H1 activator designed to promote dendritic-cell maturation and stimulate antitumor immune responses.
Which conditions is BeyondSpring, Inc. targeting with GEF-H1?
BeyondSpring, Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
What is PD-1?
Post-Immunotherapy NSCLC Strategy BeyondSpring is developing plinabulin for patients with advanced non-small cell lung cancer whose disease has progressed after PD-1 or PD-L1 therapy.
What is PD-L1?
Post-Immunotherapy NSCLC Strategy BeyondSpring is developing plinabulin for patients with advanced non-small cell lung cancer whose disease has progressed after PD-1 or PD-L1 therapy.